Completed PHASE4 INTERVENTIONAL 2-arm NCT00207311

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus (HCVNASH)

A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus

Sponsor: Brooke Army Medical Center

Conditions Fatty Liver Hepatitis C

Interventions Xenical, Pegasys, Copegus Xenicare Program

Updated 7 times since 2017 Last updated: Feb 13, 2012 Started: Aug 31, 2005 Primary completion: May 31, 2009 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00207311, this PHASE4 trial focuses on Fatty Liver and Hepatitis C and remains completed. Sponsored by Brooke Army Medical Center, it has been updated 7 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Brooke Army Medical Center
Hoffmann-La Roche
The Geneva Foundation

Data source: Brooke Army Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fort Sam Houston, United States